GlassScriptPhysician profile
Jorge Vallecillo
NPI 1538262837
$6,637.16
in general payments reported to CMS, 2019-2025
18 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,370 · 2020: $1,284 · 2021: $1,223 · 2022: $993 · 2023: $674 · 2024: $420 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,546.36 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,388.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $958.14 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $815.12 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $483.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $475.11 | 2021-2025 | |
| Verona Pharma, INC. | $230.91 | 2025 | Ohtuvayre |
| Amgen INC. | $179.06 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $134.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $113.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $91.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.25 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $48.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.63 | 2019-2022 | |
| Astellas Pharma US INC | $23.37 | 2025 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15.31 | 2023 | |
| Sanofi Pasteur INC. | $15.20 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Vallecillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.